Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Eli Lilly and Company
St. Jude Children's Research Hospital
Verismo Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
University of Arizona
Ipsen
UNC Lineberger Comprehensive Cancer Center
University of Wisconsin, Madison
AVM Biotechnology Inc
University of Nebraska
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Centre Leon Berard
St. Jude Children's Research Hospital
Baylor College of Medicine
City of Hope Medical Center
IGM Biosciences, Inc.
Cedars-Sinai Medical Center
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cyteir Therapeutics, Inc.
Nkarta, Inc.
Children's National Research Institute
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Juno Therapeutics, a Subsidiary of Celgene
University of Virginia
Cellestia Biotech AG
Corvus Pharmaceuticals, Inc.
Sunnybrook Health Sciences Centre
National Cancer Institute (NCI)
Athenex, Inc.
Rigshospitalet, Denmark
M.D. Anderson Cancer Center
Bristol-Myers Squibb